Opendata, web and dolomites


Predicting Response to Depression Treatment

Total Cost €


EC-Contrib. €






Project "PReDicT" data sheet

The following table provides information about the project.


Organization address
postcode: OX10 8BA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website
 Total cost 4˙092˙630 €
 EC max contribution 4˙092˙630 € (100%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2015
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2019-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    P1VITAL LIMITED UK (WALLINGFORD) coordinator 4˙092˙630.00


 Project objective

The objective of the Predicting Response to Depression Treatment (PReDicT) project is to conduct clinical, health economic and commercial research to validate the clinical performance and to complete the pre-commercial development of the P1vital PReDicT Test (formerly the eHealth P1vital® Oxford Emotional Test Battery (eH-ETB)), a novel medical device to improve the treatment and management of depression in clinical practice. On completion of the PReDicT project, the P1vital PReDicT Test will be ready for market launch. Depression is a common, serious and in some cases life‐threatening condition, affecting around 350 million people in the world and 11% of EU citizens suffer from depression at some point in their life. It takes 4-6 weeks after starting antidepressant treatment before a physician can detect whether the treatment is working, the majority of patients with depression do not respond to the first treatment they are prescribed and it can take several months before an effective treatment is identified. During this time a patients’ ability to work and function socially is severely impaired, and they can spend many weeks or months absent from work placing a substantial burden on the economy and healthcare resources. The P1vital PReDicT Test addresses this problem by identifying within 1 week of starting treatment whether an antidepressant is working or not which can significantly reduce the time required to identify an effective treatment. Patients benefit from this by returning to good mental health sooner. The aggregated economic cost of depression in the EU is €92 billion, amounting to 1% of the total European gross domestic product. It is estimated that the P1vital PReDicT Test has the potential to reduce these healthcare and economic costs by more than 10%. Thus the PReDicT project focuses on a patient-centric, enabling technology that not only improves efficiency and outcomes for patients but also significantly reduces socio-economic costs.


List of deliverables.
Periodic and final reports Documents, reports 2020-03-24 10:20:27
Stakeholder reports (Assessment, Engagement and Impact) Documents, reports 2020-03-11 14:35:10
Quarterly project reports Documents, reports 2020-03-11 14:35:14
Communication of results (Publications, Conference presentations, Stakeholder meetings, Press releases) Websites, patent fillings, videos etc. 2020-03-11 14:35:01
Regular project newsletters Websites, patent fillings, videos etc. 2020-03-11 14:34:57
Clinical study reports of clinical effectiveness, cost effectiveness and clinical utility Documents, reports 2020-03-11 14:35:12
Publications submitted to peer reviewed journals Documents, reports 2020-03-11 14:35:14
Interim analysis report of Part A Demonstrators, pilots, prototypes 2019-09-06 09:01:49
Study protocol finalised and approved Demonstrators, pilots, prototypes 2019-09-06 09:01:49
Initial release of eH-ETB for use in WP2 clinical study Other 2019-09-06 09:01:49
Executive leadership team established. Project and financial reporting procedures agreed Documents, reports 2019-09-06 09:01:49
Country specific Ethics approvals obtained Demonstrators, pilots, prototypes 2019-09-06 09:01:49
Technical file updated, Self-declaration of conformity and registration of eH-ETB as a Class 1 medical device Other 2019-09-06 09:01:49
Supplemental release of the eH-ETB during WP2 clinical study Other 2019-09-06 09:01:49
Study agreements executed with health centres Demonstrators, pilots, prototypes 2019-09-06 09:01:49
Project website live Websites, patent fillings, videos etc. 2019-09-06 09:01:49

Take a look to the deliverables list in detail:  detailed list of PReDicT deliverables.


year authors and title journal last update
List of publications.
2017 Jonathan Kingslake, Rebecca Dias, Gerard R. Dawson, Judit Simon, Guy M. Goodwin, Catherine J. Harmer, Richard Morriss, Susan Brown, Boliang Guo, Colin T. Dourish, Henricus G. Ruhé, Anne G. Lever, Dick J. Veltman, Anneke van Schaik, Jürgen Deckert, Andreas Reif, Michael Stäblein, Andreas Menke, Philip Gorwood, Géraldine Voegeli, Victor Pérez, Michael Browning
The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial
published pages: 558, ISSN: 1745-6215, DOI: 10.1186/s13063-017-2247-2
Trials 18/1 2019-09-06
2018 Browning, Michael
Statistical Analysis Plan for the Predict Trial
published pages: , ISSN: , DOI: 10.5281/zenodo.1235967
1 2019-09-06

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.;H2020-EU.3.1.3.)



Read More  

Respiratory-ImmunoDx (2015)

Clinical validation of host biomarker signature for distinguishing bacterial versus viral lower respiratory tract infections (LRTI) in adults at the point-of-need

Read More  

MPIPETrace (2015)

Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease.

Read More